The market for hereditary testing is predicted to expand significantly in the next years due to the rise in cancer and genetic illnesses, as well as increased knowledge and acceptance of personalized therapy. Pharmacogenomics, often known as drug-gene testing, has frequently used hereditary testing. Improvements in genetic testing methods are anticipated to accelerate market expansion.
Frequently Asked Questions
The market is segmented based on Segmentation, By Hereditary Cancer Testing (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer, Others), Hereditary Non-Cancer Testing (Genetic Tests, Newborn Genetic Screening, Preimplantation Genetic Diagnosis and Screening, Non-invasive Prenatal Testing (NIPT) and Carrier Screening Tests) – Industry Trends and Forecast to 2032
.
The Global Hereditary Testing Market size was valued at USD 2.47 USD Billion in 2024.
The Global Hereditary Testing Market is projected to grow at a CAGR of 9.15% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
